Standard BioTools Q4 2023 GAAP EPS $(0.25) Misses $(0.24) Estimate, Sales $28.19M Beat $24.90M Estimate
Portfolio Pulse from Benzinga Newsdesk
Standard BioTools (NASDAQ:LAB) reported Q4 2023 earnings with a GAAP EPS of $(0.25), missing the $(0.24) estimate by 4.17%. However, their sales of $28.19M exceeded the $24.90M estimate by 13.20%, marking a 4.32% increase from the same period last year.
February 28, 2024 | 9:05 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Standard BioTools reported a mixed Q4 2023 earnings result with a slight miss on EPS but a beat on sales, showing a year-over-year growth.
The slight miss in EPS might concern some investors, potentially putting downward pressure on the stock. However, the beat on sales and year-over-year growth could counterbalance this by indicating the company's operational strength and potential for future profitability. The mixed results make the short-term impact on the stock price uncertain, hence a neutral score.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100